Genmab — Marts 2020
-
Finanznachrichten | Börsennews | finanzen.ch
Aktuelle Finanznachrichten rund um die Börse. Hier finden Sie ständig aktuelle Berichterstattung zu allen Anlagethemen.
finanzen.ch (www.finanzen.ch)
-
du kan registrere dig til konferencen på dette link https://www.adr.db.com/drwebrebrand/resources/dbvic
-
Du kunne også vælge at sidde yderst til forelæsningerne, det gjorde jeg altid, men det var for at komme først til kantinen og få noget kaffe. Jeg ville dog bare skippe de næste 2 uger hvis jeg var i dine sko, for sandsynligheden for at skolen lukker om 2 uger er nok 80%, men det vil nok kunne aflæses på tallene de næste dage hvorvidt vi ender der. -
** Gilead's GILD.O experimental coronavirus drug remdesivir could have a benefit, but mostly for patients in early stages of the disease and with lower viral load, says Jefferies
** Brokerage's view comes after discussion with an expert who held a conservative view on chances of hugely positive trial results from ongoing remdesivir trials
** Expert tells brokerage it may be unlikely that GILD's drug is doing extremely well in China as trials are still placebo controlled and the government has no -
not yet begun administering drug to all patients - Jefferies
** Late-stage study data for remdesivir might come early April or sooner and even marginal benefit of 10%-20% would be considered success given global unmet medical need - Jefferies
** GILD up 3% at $75.80 in premarket trading
** Expert also tells brokerage that, so far analysis shows that the genetic sequence of coronavirus is relatively stable, which may bode well for vaccine and antibody developers such as Regeneron REGN.O and Moder -
Moderna MRNA.O
** Up to Monday's close, Gilead had risen 13% YTD while REGN and MRNA are up between 24%-26% for the same period -
A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab https://www.clinicaltrials.gov/ct2/show/NCT04302324?cond=Multiple+Myeloma&sfpd_s=02%2F25%2F2020&sfpd_d=14&sel_rss=new14
-
Stocks are rallying in the final hour of trading as Wall Street measures fiscal stimulus
-
Morgan Stanley raises EPS estimates for Genmab Morgan Stanley analyst Matthew Harrison maintained an Overweight rating and $31 price target on Genmab and raised his EPS estimates for FY20 and FY21.
The Fly | LANDINGPAGENEWS.PHP
Real-time market news, financial data, stock research, and portfolio tools from The Fly.
(thefly.com)
-
-
Thanks E L
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind